that’s great to just focus on the best part of the business. They should have just pumped 10 billion into the Behring side of the company. The only slim upside I see to vifor is blood collection integration through Behring, however it seems an expensive way to collect blood compared to what is proven. Just the interest expense has grown 32 percent this year. I’m all out for now, will look at it again later on.
that’s great to just focus on the best part of the business....
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$275.39 |
Change
0.900(0.33%) |
Mkt cap ! $133.0B | |||
| Open | High | Low | Value | Volume |
| $274.68 | $276.45 | $273.87 | $115.2M | 418.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 619 | $275.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $275.49 | 250 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$275.75 |
Change
0.900 ( 0.46 %) |
||||
| Open | High | Low | Volume | ||
| $275.75 | $276.43 | $273.91 | 97311 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| CSL (ASX) Chart |